Summary
COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that it has completed a $55 million Series D financing. The investor syndicate was led by Novo A/S and included new investors RA Capital, Adage Capital, Sofinnova Ventures, and one other top-tier institutional investor. The financing also included existing investors Alta Partners, Devon Park Bioventures, 3x5 Special Opportunity Fund, Salem Partners and RiverVest. Proceeds will be used to advance development of ZS-9, the Company’s lead product candidate for the treatment of hyperkalemia, through its New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions in early 2015.